Description of CJC-1295+DAC?

The CJC-1295+DAC peptide was made by ConjuChem Biotechnologies up of the first 29 amino acids of GHRH combined with a DAC supplement that allows to prolong the half-life and duration of action of the peptide CJC-1295. GHRH, the growth hormone releasing hormone, has been modified several times to create analogues that would have similar effects to GHRH, since its use is limited by short duration of action. This particular GHRH analogue was created in an attempt to find a more soluble GH secretagogue that could both be easily produced in large quantities and preserve or prolong the effects of GHRH action in the body. Although CJC-1295+DAC is chemically very similar to other GHRH analogues such as Sermorelin or even more to GRF (1-29), which is the most similar to it, they are not identical. Subcutaneous administration of CJC-1295 caused in healthy adults dose-dependent increase in GH and IGF-1 levels, which was well tolerated and safe.

[2]

Research Confirmed Effects

1. CJC-1295 and Growth Hormone Release

Studies have confirmed that after a single injection of CJC-1295 it increases growth hormone (GH) levels in mice and also in healthy human adults by about 2-10-times, with GH reaching peak levels approximately 2 hours after administration of the peptide and the effects lasting for six or more days thereafter. GHRH analogue increases also the IGF-1 concentration by 1,5-3-fold for 9-11 days, whereas the half-life was 5,8-8,1 d.

Maintaining the physiological effect on GH release is critical in affecting the maximum concentration of the hormone in the blood without adverse reaction or increased side effects. Unlike other GH secretagogues, CJC-1295 preserves normal physiological growth hormone release with unchanged frequency and magnitude of GH secretory pulses when the peptide is administered. However, basal levels of growth hormone can be increased. The CJC-1295+DAC peptide has been shown to preserve the physiological effects of GH on protein synthesis, myocardial function, bone density, hyperplasia, blood sugar, lipid metabolism or hypertrophy.

[1] [2]

2. Growth Effect and CJC-1295

Research has shown that the peptide may be potentially beneficial in normalizing growth issues. Although children with GH deficiency have a good response to GHRH administration, its therapeutical effects are limited because of very short half-life.

Research has shown that the peptide may be potentially beneficial in normalizing growth issues. Although children with GH deficiency have a good response to GHRH administration, its therapeutical effects are limited because of very short half-life.

[3]

3. CJC-1295 and Infertility

Scientists have found some in vivo and in vitro evidence that ovarian follicular cycle and ovulation is influenced and stimulated by IGF-1 hormones, and probably also by the release of growth hormone. It is for this reason that the CJC-1295 peptide, as well as other GHRH analogues, could be useful in inducing ovulation in infertile women. This is suggested by research done back in the early 1990s and confirmed by another that investigated superovulation in animals. Growth hormone and IGF-1 levels rose significantly just during ovulation and exogenous administration of growth hormone secretagogues, such as CJC-1295, induced ovulation. It has also been suggested that the peptide and other GHRH analogues could potentially act on sperm production in men and help with male infertility. Further research will, hopefully, clearly define the precise therapeutic role of GH in the induction of ovulation, and the minimum dose of GH needed to sensitize the ovary, as well as influences on men infertility.

[4]

References

1. M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006.
2. Sam L. Teichman et al., „Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults, 91(3):799-805, Epub 2005 Dec 13.
3. M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006.
4. A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no. 9, pp. 1228–1232, Oct. 1991.